Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Re-treatment of HCV Following DAA Failure

the current empiric knowledge - the choice of drugs will be based on HCV genotype, the previous treatment regimen and the presence/absence of liver cirrhosis, etc. During anti-HCV treatment

velpatasvir
sofosbuvir
liver disease
daclatasvir
ribavirin
  • 19 views
  • 02 Mar, 2022
  • 2 locations
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

A single-arm, single-center, open label Phase 1 study of a 12-week course of Sofosbuvir (SOF)/Velpatasvir (VEL) in 10 HCV-infected pregnant women 1 that will evaluate the plasma pharmacokinetic parameters of SOF/VEL administered during pregnancy and compare them to those of a historical cohort of nonpregnant women.

velpatasvir
chronic hepatitis
sofosbuvir
hepatitis b
  • 2 views
  • 12 Sep, 2021
  • 1 location
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (TARGET3D)

An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or without HIV co-infection.

  • 17 views
  • 23 Feb, 2022
  • 11 locations
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).

  • 0 views
  • 27 Apr, 2022
  • 3 locations
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection

-containing DAA regimens and HCV genotype 1a and 3 patients who fail to prior non-NS5A-containing DAA regimen in Taiwan on a basis of a multicenter observational study.

  • 0 views
  • 09 Nov, 2021
  • 15 locations
Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong

In the current era of highly effective direct acting antiviral (DAA) therapy, the remaining obstacles to elimination of chronic HCV infection are identification of the high-risk groups, linkage to continued care and prevention of re-infection. It is estimated that 70-80% of patients with chronic HCV are unaware of their infection. …

  • 0 views
  • 06 Oct, 2021
  • 1 location